Individual risk evaluation for local recurrence and distant metastasis in Ewing sarcoma: A multistate model A multistate model for Ewing sarcoma

被引:19
|
作者
Bosma, S. E. [1 ]
Rueten-Budde, A. J. [2 ]
Lancia, C. [2 ]
Ranft, A. [3 ,4 ]
Dirksen, U. [3 ,4 ]
Krol, A. D. [5 ]
Gelderblom, H. [6 ]
van de Sande, M. A. J. [1 ]
Dijkstra, P. D. S. [1 ]
Fiocco, M. [2 ,7 ]
机构
[1] Leiden Univ, Med Ctr, Dept Orthoped, Albinusdreef 2, NL-2333 ZA Leiden, Netherlands
[2] Leiden Univ, Math Inst, Leiden, Netherlands
[3] Univ Duisburg Essen, Univ Hosp Essen, West German Canc Ctr, Sarcoma Ctr,German Canc Consortium,Pediat 3, Essen, Germany
[4] German Canc Consortium DKTK, Essen, Germany
[5] Leiden Univ, Med Ctr, Dept Radiotherapy, Leiden, Netherlands
[6] Leiden Univ, Med Ctr, Dept Med Oncol, Leiden, Netherlands
[7] Leiden Univ, Med Ctr, Med Stat Biomed Data Sci, Leiden, Netherlands
基金
欧盟第七框架计划;
关键词
Ewing sarcoma; multistate model; personalized medicine; prediction; survival; PROGNOSTIC-FACTORS; CHEMOTHERAPY; TUMORS; BONE; EXPERIENCE; SURVIVAL; ADJUVANT; SURGERY; THERAPY; PROGRAM;
D O I
10.1002/pbc.27943
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background We investigated the effects of surgical margins, histological response, and radiotherapy on local recurrence (LR), distant metastasis (DM), and survival in Ewing sarcoma. Procedure Disease evolution was retrospectively studied in 982 patients with Ewing sarcoma undergoing surgery after chemotherapy using a multistate model with initial state surgery, intermediate states LR, pulmonary metastasis (DMpulm), other DM +/- LR (DMother), and final state death. Effect of risk factors was estimated using Cox proportional hazard models. Results The median follow-up was 7.6 years (95% CI, 7.2-8.0). Risk factors for LR are pelvic location, HR 2.04 (1.10-3.80), marginal/intralesional resection, HR 2.28 (1.25-4.16), and radiotherapy, HR 0.52 (0.28-0.95); for DMpulm the risk factors are <90% necrosis, HR 2.13 (1.13-4.00), and previous pulmonary metastasis, HR 4.90 (2.28-8.52); for DMother are 90% to 99% necrosis, HR 1.56 (1.09-2.23), <90% necrosis, HR 2.66 (1.87-3.79), previous bone/other metastasis, HR 3.08 (2.03-4.70); and risk factors for death without LR/DM are pulmonary metastasis, HR 8.08 (4.01-16.29), bone/other metastasis, HR 10.23 (4.90-21.36), and <90% necrosis, HR 6.35 (3.18-12.69). Early LR (0-24 months) negatively influences survival, HR 3.79 (1.34-10.76). Once DMpulm/DMother arise only previous bone/other metastasis remain prognostic for death, HR 1.74 (1.10-2.75). Conclusion Disease extent and histological response are risk factors for progression to DM or death. Tumor site and surgical margins are risk factors for LR. If disease progression occurs, previous risk factors lose their relevance. In case of isolated LR, time to recurrence is important for decision-making. Radiotherapy seems protective for LR especially in pelvic/axial. Low percentages of LR in extremity tumors and associated toxicity question the need for radiotherapy in extremity Ewing sarcoma.
引用
收藏
页数:8
相关论文
共 50 条
  • [41] Ewing sarcoma network model through EWS-FLI1 signaling
    Stoll, G.
    Surdez, D.
    Tirode, F.
    Laud-Duval, K.
    Guillon, N.
    Boeva, V.
    Delattre, O.
    Barillot, E.
    Zinovyev, A.
    EJC SUPPLEMENTS, 2010, 8 (05): : 209 - 209
  • [42] In Vitro and In Vivo Characterization of a Preclinical Irradiation-Adapted Model for Ewing Sarcoma
    Shapiro, Mary Carroll
    Tang, Tien
    Dasgupta, Atreyi
    Kurenbekova, Lyazat
    Shuck, Ryan
    Gaber, M. Waleed
    Yustein, Jason T.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2018, 101 (01): : 118 - 127
  • [43] Lyn activation is necessary for Ewing's sarcoma tumor growth in a mouse model
    Guan, Hui
    Zhou, Zhichao
    Gallick, Gary E.
    Sood, Anil K.
    Han, Liz
    Shakespeare, William C.
    Sawyer, Tomi K.
    Kleinerman, Eugenie S.
    CANCER RESEARCH, 2006, 66 (08)
  • [44] 3D tissue-engineered model of Ewing's sarcoma
    Lamhamedi-Cherradi, Salah-Eddine a
    Santoro, Marco
    Ramammoorthy, Vandhana
    Menegaz, Brian A.
    Bartholomeusz, Geoffrey
    Iles, Lakesla R.
    Amin, Hesham M.
    Livingston, J. Andrew
    Mikos, Antonios G.
    Ludwig, Joseph A.
    ADVANCED DRUG DELIVERY REVIEWS, 2014, 79-80 : 155 - 171
  • [46] Identification of an RNA-Binding-Protein-Based Prognostic Model for Ewing Sarcoma
    Chen, Yi
    Su, Huafang
    Su, Yanhong
    Zhang, Yifan
    Lin, Yingbo
    Haglund, Felix
    CANCERS, 2021, 13 (15)
  • [47] Ewing's sarcoma of kidney in a 60-year-old patient with local recurrence: A rare occurrence
    Bilgetekin, Irem
    Karaca, Mustafa
    Gonul, Ipek Isik
    Uner, Aytug
    Sahinli, Hayriye
    Demir, Hacer
    Aytekin, Aydin
    Ciltas, Aydin
    Benekli, Mustafa
    JOURNAL OF CANCER RESEARCH AND THERAPEUTICS, 2018, 14 (06) : 1422 - 1424
  • [48] Intratumor murine interleukin-12 gene therapy suppressed the growth of local and distant Ewing's sarcoma
    Jia, S-F
    Duan, X.
    Worth, L. L.
    Guan, H.
    Kleinerman, E. S.
    CANCER GENE THERAPY, 2006, 13 (10) : 948 - 957
  • [49] Intratumor murine interleukin-12 gene therapy suppressed the growth of local and distant Ewing's sarcoma
    S-F Jia
    X Duan
    L L Worth
    H Guan
    E S Kleinerman
    Cancer Gene Therapy, 2006, 13 : 948 - 957
  • [50] Zoledronic acid inhibits pulmonary metastasis dissemination in a preclinical model of Ewing's sarcoma via inhibition of cell migration
    Odri, Guillaume
    Kim, Pui-Pui
    Lamoureux, Francois
    Charrier, Celine
    Battaglia, Severine
    Amiaud, Jerome
    Heymann, Dominique
    Gouin, Francois
    Redini, Francoise
    BMC CANCER, 2014, 14